Clinical Trial Results:
Restrictive Fluid Administration vs. Standard of Care in Emergency Department Sepsis Patients - a Multicenter, Randomized Clinical Feasibility Trial
Summary
|
|
EudraCT number |
2021-000224-35 |
Trial protocol |
DK |
Global end of trial date |
18 Mar 2022
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
31 Aug 2022
|
First version publication date |
31 Aug 2022
|
Other versions |
|
Summary report(s) |
REFACED Sepsis_AcademicEmergencyMedicine_Jessen et al_2022 |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
RECEM00001
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT05076435 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Research Center for Emergency Medicine, Department of Clinical Medicine, Aarhus University
|
||
Sponsor organisation address |
Palle Juul-Jensens Boulevard 99, J103, Aarhus N, Denmark, 8200
|
||
Public contact |
Research Center for Emergency Medic, Research Center for Emergency Medicine, Department of Clinical Medicine, Aarhus University, 0045 7846 6660, cfa@clin.au.dk
|
||
Scientific contact |
Research Center for Emergency Medic, Research Center for Emergency Medicine, Department of Clinical Medicine, Aarhus University, 0045 7846 6660, cfa@clin.au.dk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
18 Mar 2022
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
18 Mar 2022
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
18 Mar 2022
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To test if an IV fluid restrictive protocol in ED patients with sepsis is feasible, i.e., if the protocol decreases the IV fluid volumes administered compared to standard care.
|
||
Protection of trial subjects |
Generally, fluid administration is considered safe and is very commonly used in clinical practice. In the restrictive fluid group protocol violations (i.e., giving fluids although no criteria are fulfillled) will be allowed if deamed needed by the treating physician. The clinical team will document any specific adverse events suspected to be related to the intervention.
|
||
Background therapy |
Standard Care fluid administration | ||
Evidence for comparator |
Fluid restriction has been suggested to be beneficial in septic shock. No evidence in sepsis patients without shock exists. Although trials are currently exploring fluid strategies in patients with hypotension and septic shock, there are no studies on fluid administration in patients with early sepsis without shock/hypotension. Research within this field has been requested by experts. As fluid administration is very frequent, but not evidence-based, and carries potential risks, we consider it to be of great interest for society and patients to perform research in this area. Fluid resuscitation is a key intervention in sepsis, but the optimal amount of fluid to be given has not been established. The present trial is a feasibility trial, i.e., a trial assessing the feasibility of the proposed protocol in a clinical setting. The aim is to investigate the ability to reduce fluid volume using the given protocol. Should the trial prove feasible with separation between the two interventions, a large-scale trial assessing patient important outcomes is intended. | ||
Actual start date of recruitment |
03 Nov 2021
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Denmark: 124
|
||
Worldwide total number of subjects |
124
|
||
EEA total number of subjects |
124
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
20
|
||
From 65 to 84 years |
75
|
||
85 years and over |
29
|
|
||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||
Recruitment details |
Nov 3rd, 2021, to Dec 18th 2021, Participants were recruited in the EDs at Aarhus University Hospital, the Regional Hospital Randers, and the Regional Hospital Viborg | |||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||
Screening details |
inclusion criteria:1) Unplanned ED admission,2) age≥18 years,3) sepsis defined as a)infection suspected,b) blood cultures drawn,c) intravenous antibiotics administered/planned, d)SOFA-score ≥ 2, and 4) expected hospital stay>24 hours, Exclusion: see protocol: DOI: 10.1186/s40814-022-01034-y / refaced-sepsis.dk | |||||||||||||||||||||
Period 1
|
||||||||||||||||||||||
Period 1 title |
Overall trial (overall period)
|
|||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||
Blinding used |
Not blinded | |||||||||||||||||||||
Blinding implementation details |
It was not possible to blind the intervention for neither the treating team, patients nor relatives.
|
|||||||||||||||||||||
Arms
|
||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||
Arm title
|
Standard care group | |||||||||||||||||||||
Arm description |
Fluids were administered by clinicians’ choice | |||||||||||||||||||||
Arm type |
Active comparator | |||||||||||||||||||||
Investigational medicinal product name |
Sodium Chloride solution 0.9%
|
|||||||||||||||||||||
Investigational medicinal product code |
13341
|
|||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
|||||||||||||||||||||
Routes of administration |
Infusion
|
|||||||||||||||||||||
Dosage and administration details |
Dose as per the treating physicians
|
|||||||||||||||||||||
Investigational medicinal product name |
Sodium chloride 9mg/ml, indsusion "Fresenius Kabi"
|
|||||||||||||||||||||
Investigational medicinal product code |
14043
|
|||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
|||||||||||||||||||||
Routes of administration |
Infusion
|
|||||||||||||||||||||
Dosage and administration details |
As per treating physician
|
|||||||||||||||||||||
Investigational medicinal product name |
Ringer-acetat "Fresenius Kabi", infusion
|
|||||||||||||||||||||
Investigational medicinal product code |
12624
|
|||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
|||||||||||||||||||||
Routes of administration |
Solution for injection
|
|||||||||||||||||||||
Dosage and administration details |
Per treating physician
|
|||||||||||||||||||||
Investigational medicinal product name |
Ringer-lactat "Fresenius Kabi", infusion
|
|||||||||||||||||||||
Investigational medicinal product code |
06756
|
|||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
|||||||||||||||||||||
Routes of administration |
Solution for infusion
|
|||||||||||||||||||||
Dosage and administration details |
As per treating physician
|
|||||||||||||||||||||
Arm title
|
Restrictive fluid administration | |||||||||||||||||||||
Arm description |
In the restrictive fluid group, intravenous crystalloid fluids should not be given unless one of the below mentioned hypoperfusion criteria were met. • Lactate concentration ≥ 4 mmol/l (arterial or venous) • Hypotension (systolic blood pressure < 90 mmHg) • Mottling beyond edge of kneecap (i.e., Mottling score >2)33 • Severe oliguria, i.e., diuresis < 0.1 ml/kg/h, during the first 4 hours of admission If one or more of these criteria were met, a fluid bolus of 250 ml isotonic crystalloid (isotonic saline or Ringer’s acetate/lactate) could be administered per protocol. It was not a requirement that a fluid bolus was administered. | |||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||
Investigational medicinal product name |
Sodium Chloride solution 0.9%
|
|||||||||||||||||||||
Investigational medicinal product code |
13341
|
|||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
|||||||||||||||||||||
Routes of administration |
Infusion
|
|||||||||||||||||||||
Dosage and administration details |
Dose as per the restrictive protocol
|
|||||||||||||||||||||
Investigational medicinal product name |
Sodium chloride 9mg/ml, indsusion "Fresenius Kabi"
|
|||||||||||||||||||||
Investigational medicinal product code |
14043
|
|||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
|||||||||||||||||||||
Routes of administration |
Infusion
|
|||||||||||||||||||||
Dosage and administration details |
As per treating physician or per trial protocol
|
|||||||||||||||||||||
Investigational medicinal product name |
Ringer-acetat "Fresenius Kabi", infusion
|
|||||||||||||||||||||
Investigational medicinal product code |
12624
|
|||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
|||||||||||||||||||||
Routes of administration |
Solution for injection
|
|||||||||||||||||||||
Dosage and administration details |
Per treating physician or per restrictive protocol
|
|||||||||||||||||||||
Investigational medicinal product name |
Ringer-lactat "Fresenius Kabi", infusion
|
|||||||||||||||||||||
Investigational medicinal product code |
06756
|
|||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
|||||||||||||||||||||
Routes of administration |
Solution for infusion
|
|||||||||||||||||||||
Dosage and administration details |
As per treating physician or per restrictive protocol
|
|||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Standard care group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Fluids were administered by clinicians’ choice | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Restrictive fluid administration
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
In the restrictive fluid group, intravenous crystalloid fluids should not be given unless one of the below mentioned hypoperfusion criteria were met. • Lactate concentration ≥ 4 mmol/l (arterial or venous) • Hypotension (systolic blood pressure < 90 mmHg) • Mottling beyond edge of kneecap (i.e., Mottling score >2)33 • Severe oliguria, i.e., diuresis < 0.1 ml/kg/h, during the first 4 hours of admission If one or more of these criteria were met, a fluid bolus of 250 ml isotonic crystalloid (isotonic saline or Ringer’s acetate/lactate) could be administered per protocol. It was not a requirement that a fluid bolus was administered. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Standard care group
|
||
Reporting group description |
Fluids were administered by clinicians’ choice | ||
Reporting group title |
Restrictive fluid administration
|
||
Reporting group description |
In the restrictive fluid group, intravenous crystalloid fluids should not be given unless one of the below mentioned hypoperfusion criteria were met. • Lactate concentration ≥ 4 mmol/l (arterial or venous) • Hypotension (systolic blood pressure < 90 mmHg) • Mottling beyond edge of kneecap (i.e., Mottling score >2)33 • Severe oliguria, i.e., diuresis < 0.1 ml/kg/h, during the first 4 hours of admission If one or more of these criteria were met, a fluid bolus of 250 ml isotonic crystalloid (isotonic saline or Ringer’s acetate/lactate) could be administered per protocol. It was not a requirement that a fluid bolus was administered. |
|
|||||||||||||
End point title |
Crystalloid fluid volumes (24 h) | ||||||||||||
End point description |
(NaCl and Ringers administered in 24 hours)
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
24 hours
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Quantile regression | ||||||||||||
Comparison groups |
Standard care group v Restrictive fluid administration
|
||||||||||||
Number of subjects included in analysis |
123
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Quantile regression (median regression) | ||||||||||||
Parameter type |
Median difference (final values) | ||||||||||||
Point estimate |
-1000
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-1392 | ||||||||||||
upper limit |
-607 | ||||||||||||
Variability estimate |
Standard deviation
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information [1]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
90 days
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
eddra
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Restrictive fluid administration
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Standard Care
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: We experienced no adverse events as defined by the protocol |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None to report |